Focused On-demand Library for F-box only protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UKT5

UPID:

FBX4_HUMAN

Alternative names:

Alternative UPACC:

Q9UKT5; Q68CU8; Q86VT8; Q9UK98

Background:

F-box only protein 4 plays a crucial role in cellular processes as a substrate recognition component of the SCF E3 ubiquitin-protein ligase complex. It mediates ubiquitination and proteasomal degradation of target proteins, including CCND1, TERF1, and FXR1, the latter following phosphorylation by GSK3B. This protein's ability to regulate protein stability underscores its importance in cell cycle control and signal transduction.

Therapeutic significance:

Understanding the role of F-box only protein 4 could open doors to potential therapeutic strategies. Its involvement in the ubiquitination and degradation of key proteins suggests a pivotal role in cellular regulation, which, if modulated, could offer new avenues for the treatment of diseases where protein degradation and cell cycle control are compromised.